Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

Recruiting

Phase 2

RosuvastatinLiver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

Sponsor:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Code:

NCT05832229

Conditions

Cirrhosis

Cirrhosis, Liver

Cirrhosis Early

Cirrhosis Due to Hepatitis B

Cirrhosis Advanced

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Rosuvastatin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-17. This information was provided to ClinicalTrials.gov by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) on 2024-12-17.